PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
For research use only. We do not sell to patients.
- CAS No.: 202350-68-3
- Formula: C32H35NO13
- Molecular Weight:641.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | EC50 |
0.37 pM
Compound: 1; PNU-159682
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability
Cytotoxicity against HEK293T cells assessed as reduction in cell viability
|
[PMID: 33127540] |
| MES-SA | EC50 |
0.2 pM
Compound: 1; PNU-159682
|
Cytotoxicity against human MES-SA cells assessed as reduction in cell viability
Cytotoxicity against human MES-SA cells assessed as reduction in cell viability
|
[PMID: 33127540] |
| MES-SA/Dx5 | EC50 |
0.38 pM
Compound: 1; PNU-159682
|
Cytotoxicity against human MES SA/DX5 cells assessed as reduction in cell viability
Cytotoxicity against human MES SA/DX5 cells assessed as reduction in cell viability
|
[PMID: 33127540] |
Chemical Information
-
CAS No. 202350-68-3
-
Molecular Weight 641.62
-
Formula C32H35NO13
-
SMILES
COC1=C(C(C(C(O)=C([C@@H](O[C@H]2C[C@H]3[C@H](O[C@H]4N3CCO[C@@H]4OC)[C@H](C)O2)C[C@@](C(CO)=O)(O)C5)C5=C6O)=C6C7=O)=O)C7=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Quintieri L, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res. 2005 Feb 15;11(4):1608-17. [Content Brief]
[2]. Cazzamalli S, et al. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma. Mol Cancer Ther. 2016 Dec;15(12):2926-2935. [Content Brief]
[3]. Pengxuan Zhao, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020 Sep;10(9):1589-1600. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)